Guardant Health

Guardant Health makes blood tests that help doctors find and monitor cancer. Its tests guide treatment choices and screen for early signs of disease. These tools help patients and healthcare providers make informed decisions about cancer care.

Products and Services

• Precision Oncology Testing (93% of 2024 revenue): Blood and tissue tests for cancer detection, therapy selection, and monitoring, used by doctors and hospitals.
• Early Cancer Screening: Shield test for colorectal cancer screening in adults, with Medicare coverage and FDA approval.
• Biopharma Services: Testing and data services for pharmaceutical companies developing new cancer drugs.
• Data and Analytics: GuardantINFORM platform provides clinical-genomic datasets for research and drug development.
• Software Solutions: GuardantConnect matches patients to clinical trials based on test results.
• COVID-19 Testing: Guardant-19 test for coronavirus detection, mainly for healthcare clients.

Growth and Expansion

• Launched Shield blood test for colorectal cancer screening in the US in August 2024.
• Expanded internationally through partnerships with VHIO (Spain), Royal Marsden (UK), Gemelli (Italy), and Adicon (China) from 2022 to 2024.
• Entered Japanese market with regulatory and reimbursement progress for Guardant360 CDx in 2023-2024.
• Broadened product line to include early detection, recurrence monitoring, and multi-cancer screening from 2022 onward.
• Collaborated with leading cancer centers and research organizations to support clinical studies and product validation.

What Makes Guardant Health Stand Out

Guardant Health operates globally, offering a wide range of cancer tests for different stages of care. Its technology combines advanced blood analysis, DNA sequencing, and machine learning to detect cancer signals. The company’s proprietary data assets and strategic partnerships support research and product development.

Five Things You Need to Know

• Total revenue was $739.0 million in 2024, up 31% from 2023.
• Clinical precision oncology testing made up 73.5% of 2024 revenue, up 34% year-over-year.
• Biopharma testing revenue was $145.1 million in 2024, up 31% from 2023.
• Operating loss was $443.6 million in 2024, improved from $564.7 million in 2023.
• Cash, equivalents, and marketable securities totaled $944.2 million at December 31, 2024.

Bottom Line

Guardant Health has grown by expanding its cancer testing portfolio and global reach. The company continues to invest in innovation and partnerships to address evolving needs in cancer care.